Showing 5111-5120 of 7158 results for "".
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- AbbVie, BTL Settle Patent Disputehttps://practicaldermatology.com/news/abbvie-btl-settle-patent-dispute/2460906/BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the terms of the settlement agreement, AbbVie will pay BTL an undisclosed payment. The details of the agreement are confidential and will not be disc
- Sciton Rolls Out BBLINK Goggles for Improved Eye Protectionhttps://practicaldermatology.com/news/sciton-rolls-out-bblink-goggles-for-improved-eye-protection/2460903/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technol
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- Business News: Crown Labs to Acquire StriVectinhttps://practicaldermatology.com/news/business-news-crown-labs-acquire-strivectin/2460897/Crown Laboratories is slated to acquire StriVectin from the private equity firm L Catterton. The transaction is expected to close by mid-September and is subject to regulatory approvals and other customary closing conditions. Terms of the transaction were not disclosed.
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- New Gel Shows Promise Against BCChttps://practicaldermatology.com/news/new-gel-shows-promise-against-bcc/2460890/Medivir AB’s topical histone deacetylase (HDAC) inhibitor remetinostat performed well in a phase II study in basal cell carcinoma (BCC), according to research published online in Clinical Cancer Research. The new gel could reduce the need for surgical
- FDA Accepts Dermavant's NDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-dermavants-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis/2460886/The FDA has accepted Dermavant Sciences' New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to